Merck
CN
HomeWebinarsWhat’s Really in the Box? Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS

What’s Really in the Box? Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS



WEBINAR

Due to the nature of AAV particle production, non-targeted sequences may be packaged along with the gene of interest.  Even in an optimized system, these non-target nucleic acids can comprise between 1-2% or greater of the entire nucleic acid payload. Characterizing the non-targeted sequences that may be packaged in the vector is important for establishing the safety profile of the final product.

NGS can provide a clearer picture of all encapsidated sequences within the AAV particles. In this webinar, we discuss the characterization of several representative AAV molecules using NGS, including the sequencing process, bioinformatic analysis, and representative results.

In this webinar, we will explore:

  • How NGS can provide broad characterization of targeted and non-targeted sequences packaged in an AAV particle
  • The process for evaluating encapsidated residual sequences in an AAV sample
  • Concepts for the determination of nucleic acid content of full, partial, and empty capsids

Speaker

Bradley Hasson

Bradley Hasson

Merck

Director of Lab Operations for NGS Services

Bradley Hasson is the director of lab operations for next-generation sequencing services. Brad leads a team of scientists, laboratory technicians, and bioinformaticians that perform NGS-based biosafety testing services in support of product characterization and release worldwide.

Brad has 15 years of experience developing and implementing molecular-based methods for the purposes of lot release and characterization testing in a variety of biologically derived products.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?